Supply Chain Concerns Regarding APIs and Logistics: Survey

The effect of the COVID-19 pandemic has constrained pharmaceutical organizations to reconsider their supply chains including reshoring manufacturing of APIs, intermediates, and different products.

GlobalData has led an overview to evaluate the significant business supply chain worries for pharma organizations in the midst of the COVID-19 pandemic. The organizations were arranged into two classes with the end goal of the overview – organizations with predominantly promoted drugs​ and organizations with pipeline and marketed drugs​.

Supply chain risks related with API chemicals were the greatest worry for organizations with dominatingly promoted drugs, as communicated by a greater part 27% of the respondents in Q1, which expanded to 29% in Q3.

The following greatest worry for them was API intermediates, with around 19% of the organizations deciding in favor of it in Q1, contrasted with 14% in Q3. Concern over the equivalent was lesser for organizations with pipeline and marketed drugs, at 11% in Q1, which expanded to 13% in Q3.